Hepatic encephalopathy (HE) is a common complication of advanced liver disease. The first-line treatment includes agents that counter the high levels of ammonia, which are thought to play a central role in the disease.
- What information do ammonia measurements provide and what is the relationship with hepatic encephalopathy?
- Is the term “Covert HE” clinically useful?
- And, is it time to rethink the standard of care?
Discussions in this EASL Studio JHEP Live episode will revolve around a recently published article. In addition, the Q&A summary is displayed below the video. Please login to your free EASL Campus account to share your questions and thoughts using the forum available on this page!
This EASL studio is supported by Norgine and Umecrine Cognition. EASL has received no input from Norgine and Umecrine Cognition with regards to the content of this programme.
ℹ️ Please click here to access the podcast version of this EASL Studio episode.